Document is current
Any future updates will be listed below
-
Authors
Franz, Jonas
Ng, Tat Fong
Gupta, Shivali
Wilson, Mark R.
Fini, M. Elizabeth
Masli, Sharmila
-
Funding
Funding for this research was provided by:
National Institutes of Health (R41EY034396)
- License Information
-
More Information
Article History
Received: 9 June 2025
Accepted: 11 February 2026
First Online: 15 February 2026
Declarations
:
: M.E.F. is a co-founder of Proteris Biotech and an employee of the company, serving as Chief Scientific Officer. S.M. and M.R.W. hold equity in Proteris Biotech and serve on the Medical and Scientific Advisory Board. She is also affiliated with the New England Eye Center, Tufts Medical Center and the Department of Ophthalmology, Tufts University School of Medicine, Boston MA 02115 USA. M.E.F. is named as a co-inventor on U.S. patent number 9241974 entitled “Clusterin Pharmaceuticals and Treatment Methods Using the Same” granted to the University of Southern California and optioned for exclusive license to Proteris Biotech. S.M. and M.E.F. are named as co-inventors on a preliminary U.S. patent application co-submitted by Boston University and Proteris Biotech, claiming some of the new findings of this study (63/734,859). All other authors declare that they do not have any competing interest.
